Gary Ginsberg Buys Shares of SDGR $SDGR

Key Points

  • Gary Ginsberg bought 13,313 shares of Schrödinger, Inc. ($SDGR).
  • $SDGR last traded around $15.04.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Gary Ginsberg, insider at Schrödinger, Inc. ($SDGR), bought 13,313 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Schrödinger, Inc. Stock Down 23.7%

Shares of Schrödinger, Inc. ($SDGR) traded around $15.04 on Wednesday, down 23.7% for the day.

Last price$15.04
Market cap$1.46B
Forward P/E-14.44
Beta1.66
52-week low$10.95
52-week high$23.02
50-day MA$16.86
200-day MA$15.04
Current ratio2.71
Quick ratio2.62
Debt-to-equity0.33

Schrödinger, Inc. Earnings

EPS (ttm)-$0.72
Revenue (ttm)$259.04M
Revenue growth7.50%
Net margin-20.98%
Return on equity-16.17%
Next earningsNov 4, 2026

Analysts Set New Price Targets

Average target$21.43
High target$30
Low target$17
Analysts covering7

About Schrödinger, Inc.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

ExchangeNasdaqGS
SectorHealthcare
IndustryHealth Information Services
HeadquartersNew York, NY
CEODr. Ramy Farid Ph.D.
Employees850

Get Schrödinger, Inc. alerts

New 13F filings, insider trades, and analyst moves on $SDGR, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.